947249-01-6

Basic information

• Product Name: 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester
• Synonyms: 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester;5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-trifluoromethyl)pyridin-2-amine;3-(trifluoroMethyl)-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-aMine;6-Amino-5-(trifluoromethyl)pyridine-3-boronic acid pinacol ester;3-hydroxy-2,3-dimethylbutan-2-yl hydrogen (6-amino-5-(trifluoromethyl)pyridin-3-yl)boronate
• CAS NO: 947249-01-6
• Molecular Formula: C₁₂H₁₆BF₃N₂O₂
• Molecular Weight: 306.0891296
• Mol File: 947249-01-6.mol

Chemical Properties

• Melting Point: 132-134℃
• Boiling Point: 359.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.23
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: 4.31±0.50(Predicted)
• CAS DataBase Reference: 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester(947249-01-6)
• EPA Substance Registry System: 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester(947249-01-6)

Safety Data

• Hazardous Substances Data: 947249-01-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester is utilized as a reagent in the preparation of a range of pharmaceuticals and agrochemicals. Its involvement in the synthesis process is crucial for the development of new drugs and agricultural compounds, enhancing their efficacy and properties.
Used in Organic Synthesis:
In the field of organic chemistry, 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester is employed as a key component in Suzuki-Miyaura coupling reactions. These reactions are pivotal for the formation of carbon-carbon bonds, which are fundamental in constructing complex organic molecules.
Used in Suzuki-Miyaura Coupling Reactions:
2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid pinacol ester is used as a coupling partner in Suzuki-Miyaura coupling reactions for the formation of carbon-carbon bonds. Its participation in these reactions is essential for creating diverse organic compounds with potential applications in various industries.
Used in Enhancing Stability and Solubility:
The pinacol ester form of 2-Amino-3-(trifluoromethyl)pyridine-5-boronic acid contributes to the compound's stability and solubility. This enhancement makes the compound more manageable and practical to use in chemical reactions, facilitating its integration into various synthesis processes.

Upstream product

• 183610-70-0 2-amino-3-trifluoromethylpyridine 
• 79456-34-1 5-bromo-3-(trifluoromethyl)pyridin-2-amine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1083429-59-7 N-(2-{4-[3-(6-amino-5-trifluoromethyl-pyridin-3-yl)-2-methyl-imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenoxy}-ethyl)-4-morpholin-4-yl-benzamide 
• 1083429-55-3 1-(3-{5-[3-(6-amino-5-trifluoromethyl-pyridin-3-yl)-2-methyl-imidazo[1,2-b]pyridazin-6-yl]-2-methoxy-phenoxy}-propyl)-3-(3-methoxy-phenyl)-urea 
• 1083430-94-7 C₂₈H₃₁F₃N₆O₄ 
• 1083430-95-8 5-{6-[3-(3-amino-propoxy)-4-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-3-yl}-3-trifluoromethyl-pyridin-2-ylamine 
• 1083428-92-5 5-{6-[4-(2-amino-ethoxy)-3-methoxy-phenyl]-2-methyl-imidazo[1,2-b]pyridazin-3-yl}-3-trifluoromethyl-pyridin-2-ylamine 
• 1084951-43-8 5-(3-(6-(4-phenylthiazol-2-ylamino)pyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl)-3-trifluoromethylpyridin-2-ylamine 
• 1084951-48-3 5-(3-(4-ethanesulfonylphenyl)imidazo[1,2-b]pyridazin-6-yl)-3-trifluoromethylpyridin-2-ylamine 
• 1366050-29-4 2-(4-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1366047-63-3 2-(4-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-1-yl)phenyl)-2-methylpropanenitrile 
• 1360177-17-8 4-[5-(6-amino-5-trifluoromethyl-pyridin-3-yl)-imidazo[2,1-b][1,3,4]thiadiazol-2-ylamino]-cyclohexanone 

Relevant articles and documents

Fit-for-purpose synthesis of dual leucine zipper kinase (DLK) inhibitor GNE-834

A practical fit-for-purpose synthesis of dual leucine zipper kinase (DLK) inhibitor GNE-834 (1) was developed. The key C[sbnd]C bond was constructed via a Suzuki–Miyaura cross-coupling of iodopyrazole 2 and pyridine boronic ester 3 to afford ketone 12. Su

2-MORPHOLIN-4,6-DISUBSTITUTED PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF

Disclosed is a 2-morpholin-4,6-disubstituted pyrimidine derivative as shown in formula (I) below, and a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, and a pharmaceutical composition thereof and a use thereof, wherein the definition of each group is as shown in the description. The compound has a PI3K kinase inhibition activity, and has a relatively high inhibitive ability and a low cytotoxicity against PIK3CA mutant breast cancer cell strains T47D and MCF-7.

PROCESS FOR THE PREPARATION OF SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, INTERMEDIATES AND POLYMORPHS THEREOF

The present invention relates to a process for preparation of substituted imidazo[4,5- c]quinoline compounds (the compounds of formula I as described) and intermediates thereof. The present invention also relates to polymorphs of a compound encompassed in the compound of formula I and their use in the treatment of proliferative disorders, particularly cancers.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K

PI3 kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration and differentiation. The PI3 Kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations and PTEN p

FUSED HETEROARYLS AND THEIR USES

Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.

FUSED HETEROARYLS AND THEIR USES

Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.

1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.

PI3K/M TOR INHIBITORS

The invention relates to PI3K/mTOR inhibiting compounds consisting of the formula (I): wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; meth